Author/Authors :
Kigitovica, Dana Department of Internal Diseases - Riga Stradins University - Riga - Latvia , Šablinskis, Matiss Medical Faculty - Riga Stradins University - Riga - Latvia , Lejniece, Sandra Department of Internal Diseases - Riga Stradins University - Riga - Latvia , Lejnieks, Aivars Department of Internal Diseases - Riga Stradins University - Riga - Latvia , Skride, Andris Department of Internal Diseases - Riga Stradins University - Riga - Latvia
Abstract :
A systematic review has reported that the prevalence of
connective tissue disease (CTD)-associated pulmonary arterial
hypertension (PAH) is estimated to be 13% (1). The latest guidelines recommend monotherapy with ambrisentan for patients
in World Health Organization functional class (WHO-FC) II (2),
which offers a relative lack of drug interactions and safety (3).
